以下文章来源于投资家 ，作者云帆 投资家 . 投资家是投资家网旗下专注创投、商业、科技领域的内容平台。多次获得百度、头条、新浪、网易、搜 狐、东财、同花顺、澎湃等颁发的荣誉奖项。投资家网是国内知名资本与产业创新综合服务平台。 作者： 云帆 来源： 投资家 这家炮制骗局的 A 股上市公司，妄想谎言梦碎前，狠狠坑一波股民。最近，靠一支"童颜针"火遍 医美界的吴中美学关联母公司江苏吴中（ *ST 苏吴）连续五日涨停后，突然停牌。监管查出， *ST 苏吴长期造假、掏空资产，性质恶劣，随即对其启动重大违法强制退市措施 。 值得一提的是，两个月前，吴中美学还在社交平台"伸张正义"，发布"关于高举法律武器维护自身 合法权益的严正宣告"。 彼时，"吴中美学与医美龙头爱美客及韩国子公司 Regen ，就医美产品 AestheFill 的中国境内独 家经销权发生纠纷。"这件事在医美界闹得沸沸扬扬，也使吴中美学备受外界关注。 吴中美学曾发文称，"人无信不立，业无信不兴。"指责" Regen 公司恶意违约，随意践踏契约精 神。"爱美客卷入风波，股价暴跌，被外界喷的体无完肤。谁都没想到，两个月后风云莫测，"医美 界最大黑马"江苏吴中成 ...

Core Viewpoint - The arbitration progress regarding the exclusive agency rights for "AestheFill" between Aimeike and *ST Suwu has led to significant market reactions, with Aimeike's stock declining and *ST Suwu's stock increasing on the same day [1][2]. Group 1: Arbitration Details - The Shenzhen International Arbitration Court ruled that Aimeike's subsidiary, Regen Biotech, cannot sell "AestheFill" in mainland China and must recognize Datou Medical as the exclusive distributor [1][3]. - Datou Medical's request for additional temporary measures, including the revocation of the exclusive authorization for Lizhen (Xiamen) Medical Technology Co., Ltd., was not granted [2][6]. - The emergency arbitrator confirmed that Datou Medical remains the undisputed exclusive distributor of "AestheFill" in mainland China until a final arbitration decision is made [3][5]. Group 2: Financial Impact - *ST Suwu reported a 27.08% year-on-year decline in revenue for the first half of the year, totaling 636 million yuan, with a net loss of approximately 44.42 million yuan, a 281.63% decrease [7]. - Aimeike's revenue for the same period was 1.299 billion yuan, down 21.59% year-on-year, with a net profit of 789 million yuan, reflecting a 29.57% decline [7]. Group 3: Future Implications - The ongoing arbitration will significantly impact both companies' strategies and developments in the medical aesthetics market, with the arbitration court set to form a tribunal for further proceedings [8].

Core Viewpoint - Jiangsu Wuzhong's subsidiary, Datou Medical, has received a termination letter from Regen Biotech, which demands the cancellation of Datou Medical's exclusive distribution rights for the AestheFill product in mainland China, raising concerns about the company's future in the medical aesthetics sector amid ongoing financial scandals [1][2]. Group 1: Company Response and Legal Actions - Jiangsu Wuzhong has initiated a response plan upon receiving the termination letter and is in communication with Regen, indicating that legal action may be taken if necessary to protect its rights [2]. - Regen's reasons for termination include allegations that Datou Medical transferred exclusive distribution rights to its parent company, and concerns over Jiangsu Wuzhong's legal violations affecting the product's reputation [2]. Group 2: Market Impact and Financial Performance - The change in the registration agent for AestheFill from Datou Medical to Lizhen (Beijing) Biotechnology Co., owned by Regen, introduces uncertainty regarding the previously secure exclusive distribution agreement [4]. - In 2024, Jiangsu Wuzhong reported a revenue of 1.599 billion yuan, a decline of 28.64% year-on-year, with the medical aesthetics segment generating 330 million yuan, a significant increase of over 40 times [4]. - If the exclusive distribution agreement is ultimately terminated, Datou Medical would lose its rights to sell AestheFill, leading to a substantial decrease in revenue and profit for the medical aesthetics segment in the latter half of the year [5].